Canavan's disease is an autosomal recessive disorder caused by aspartoacylase deficiency. The deficiency of aspartoacylase leads to increased concentration of N-acetylaspartic acid in brain and body fluids. The failure to hydrolyze N-acetylaspartic acid causes disruption of myelin, resulting in spongy degeneration of the white matter of the brain. The clinical features of the disease are hypotonia in early life, which changes to spasticity, macrocephaly, head lag, and progressive severe mental retardation. Although Canavan's disease is panethnic, it is most prevalent in the Ashkenazi Jewish population. Research at the molecular level led to the cloning of the gene for aspartoacylase and development of a knockout mouse for Canavan's disease. These developments have afforded new tools for research in the attempts to understand the pathophysiology of Canavan's disease, design new therapies, and explore methods for gene transfer to the central nervous system. (J Child Neurol 2003;18:604—610).
van Bogaert L., Bertrand I.: Sur une idiotie familiale avec degerescence sponglieuse de neuraxe (note preliminaire). Acta Neurol1949;49:572—587.
3.
Matalon R., Michals K., Sebasta D., et al: Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet1988;29:463—471.
4.
Matalon R., Rady PL, Platt KA, et al: Knock out mouse for Canavan disease: A model for gene transfer to the central nervous system. J Gene Med2000;2:165—175.
5.
Buchanan DS, Davi RL: Spongy degeneration of the nervous system: A report of 4 cases with a review of the literature. Neurology1965;15:207—222.
6.
Kaul R., Balamurugan K., Gao GP, Matalon R.: Canavan disease: Genomic organization and localization of human ASPA to 17p13-ter: Conservation of the ASPA gene during evolution. Genomics1994;21:364—370.
7.
Kaul R., Gao GP, Aloya M., et al: Canavan disease: Mutations among Jewish and non-Jewish patients . Am J Hum Genet1994;55:34—41.
8.
Kaul RK, Matalon R., Gao GP, et al: Spectrum of Canavan mutations among Jewish and non Jewish patients . Am J Hum Genet1994;55(Suppl):212.
9.
Kronn D., Oddoux C., Phillips J., et al: Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish individuals. Am J Hum Genet1995;57:1250—1252.
10.
Elpeleg ON, Anikster Y., Barash V., et al: The frequency of C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. Am J Hum Genet1994 ;55:287—288.
11.
Matalon R., Michals-Matalon K.: Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings. Pediatr PatholMol Med2000;18:471—481.
12.
Matalon R., Michals-Matalon K.: Molecular basis of Canavan disease. Eur J PaediatrNeurol1998;2:69—76.
13.
Matalon RM, Michals-Matalon K.: Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings. Front Biosci2000;5:D307—D311.
14.
Rushton AR, Shaywitz BA, Dumen CC, et al: Computerized tomography in the diagnosis of Canavan disease . Ann Neurol1981; 10:57—60.
15.
Brismar J., Brismar G., Gascon G., Ozand P.: Canavan disease: CT and MR imaging of the brain. Am J Neurol Res1990;11:805—810.
16.
Matalon R., Michals K., Kaul R., Mafee M.: Spongy degeneration of the brain, Canavan disease. Int Pediatr1990;5:121—124.
17.
Grodd W., Kragaloh-Mann I., Peterson D., et al: In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan disease) by proton spectroscopy. Lancet1990;336:437—438.
18.
Wittsack HJ , Kugel H., Roth B., Heindel W.: Quantitative measurements with localized 1H NMR spectroscopy in children with Canavan disease. J Magn Reson Imaging1996;6:889—893.
19.
Ory-Lavolle L., Blakely RD, Coyle JT: Neurochemical and immunochemical studies on the distribution of N-acetylaspartylglutamate and N-acetylaspartate in the rat spinal cord and some peripheral nervous tissues. J Neurochem1987;48:895—899.
20.
Sager TN, Thomsen C., Valsborg JS, et al: Astroglia contains a specific transport mechanism for N-acetyl-L-aspartate . J Neurochem1999;73:807—811.
21.
Adornato BT , O'Brien JS, Lampert PW: Cerebral spongy degeneration of infancy: A biochemical and ultrastructural study of affected twins. Neurology1972;22:202—210.
22.
Baslow MH: Molecular water pumps and the aetiology of Canavan disease: A case of the sorcerer's apprentice. J Inherit Metab Dis1999;22:99—101.
23.
Adachi M., Torii J., Schneck L., Volk BW: Electron microscopic and enzyme histochemical studies of the cerebellum in spongy degeneration (van Bogaert and Bertrand type). Acta Neuropathol (Berl)1972;20:22—31.
24.
Luo Y., Huang K.: Spongy degeneration of the CNS in infancy. Arch Neurol1984;41:164—170.
25.
Matalon R., Michals-Matalon K.: Recent advances in Canavan disease. Adv Pediatr1999;46:493—506.
26.
Kaul RK, Gao GP, Balamurugan K., Matalon R.: Human aspartoacylase cDNA and mis-sense mutation in Canavan disease. Nat Genet1993;5:118—123.
27.
Matalon R., Kaul R., Michals K.: Carrier rate of Canavan disease among Ashkenazi Jewish individuals. Am J Hum Genet1994; 55:A157.
28.
Shaag A., Anikster Y., Christensen E., et al: The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients. Am J Hum Genet1995;57:572—580.
29.
Kobayashi K. , Tsujino S., Ezoe T., et al: A missense mutation I143T in a Japanese patient with Canavan disease. Hum Mutat Suppl 1998;1:S308—S309.
30.
Olsen TR, Tranebjaerg L., Kvittingen EA, et al: Two novel aspartoacylase (ASPA) gene missense mutations specific to Norwegian and Swedish patients with Canavan disease. J Med Genet2002;39:e55.
31.
Propheta O. , Magal N., Shohat M., et al: A benign polymorphism in the aspartoacylase gene may cause misrepresentation of Canavan gene testing. Eur J Hum Genet1998;6:635—637.
32.
Alford RL, DeMarchi JM, Richards CS: Frequency of a DNA polymorphism at position Y231 in the aspartoacylase gene and its impact on DNA-based carrier testing for Canavan disease in an Ashkenazi Jewish population. Hum Mutat Suppl 1998; 1:S161-S162.
33.
Elpeleg ON, Shaag A., Anikster Y., Jakobs C.: Prenatal detection of Canavan disease (aspartoacylase deficiency) by DNA analysis . J Inherit Metab Dis1994; 17:664-666.
34.
Matalon R., Kaul R., Gao GP: Prenatal diagnosis for Canavan disease: The use of DNA markers. J Inherit Metab Dis1995; 18:215—217.
35.
Bennett MJ, Gibson KM, Sherwood WG, et al: Reliable prenatal diagnosis of Canavan disease (aspartoacylase deficiency): Comparison of enzymatic and metabolite analysis. J Inherit Metab Dis1993;16:831—836.
36.
Kelley RI: Prenatal diagnosis of N-acetyl-L-aspartate in amniotic fluid. J Inherit Metab Dis1993;16:918—919.
37.
Bluml S., Seymour K., Philippart M., et al: Elevated brain water in Canavan disease: Impact of a diuretic therapy. Int Soc Magn Res1998;171.
38.
Crystal RG: Transfer of genes to humans: Early lessons and obstacles to success. Science1995;270:404—410.
39.
McDonnell TJ , Meyn RE, Robertson LE: Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol1995;6:53—60.
40.
Leone P., Janson CG, Bilanuk L.: Aspartoacylase gene transfer to the central nervous system with therapeutical implications for Canavan disease. Ann Neurol2000;48:27—38.
41.
Matalon R., Rady P., Surendran S., et al: Delivery of rAAV-aspartoacylase in a knock out mouse for Canavan disease, abstract. J Inherit Metab Dis2001 ;24(Suppl 1):123.
Wu P., Phillips M., Bui J., et al: Adenoassociated virus mediated trans-gene integration into neurons and other nondividing cell targets. J Virol1998;72:5919—5926.
44.
Xiao X., Li J., McCown TJ, et al: Gene transfer by adenoassociated virus vectors into the central nervous system. Exp Neurol1997; 144:113—124.
